InNexus Teams With Mayo Clinic to Develop Antibodies

InNexus Biotechnology announced a multiyear collaborative research agreement with Mayo Clinic aimed at advancing the leading science of monoclonal antibody development, and for the creation of promising new medicines for cancer, cardiovascular disease and other difficult-to-treat diseases. "The mission of our collaboration is to develop new therapies, and we believe that combining forces with an outstanding institution such as Mayo Clinic will help to continue InNexus' innovative work in developing SuperAntibodies," said Dr. Charles Morgan, president and CEO of InNexus.

Canada Newswire Group (http://www.newswire.ca/en/releases/archive/May2005/17/c0175.html)